VANRAFIA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VANRAFIA (VANRAFIA).
Vanrafia acts as a selective inhibitor of the sodium-glucose cotransporter-2 (SGLT2) in the proximal renal tubule, reducing renal glucose reabsorption and increasing urinary glucose excretion, thereby lowering blood glucose levels.
| Metabolism | Vanrafia undergoes minimal metabolism via glucuronidation by UGT1A9 and UGT2B7; primarily excreted unchanged in urine. |
| Excretion | Primarily via feces (80–90%) as unchanged drug and metabolites; renal excretion accounts for <5%. |
| Half-life | Terminal elimination half-life is 120–216 hours (5–9 days) in healthy volunteers; prolonged in hepatic impairment. |
| Protein binding | 99% bound primarily to serum albumin. |
| Volume of Distribution | Vd is approximately 0.11–0.20 L/kg, reflecting distribution mainly in plasma and interstitial fluid. |
| Bioavailability | Oral: 95–100% with minimal first-pass metabolism; interindividual variability due to CYP2C9 and VKORC1 polymorphisms. |
| Onset of Action | Oral: 2–5 days to achieve therapeutic INR; IV: 12–24 hours for initial suppression of vitamin K-dependent factors. |
| Duration of Action | Anticoagulant effect persists for 48–96 hours after single dose; recovery of clotting factors may take 7–10 days upon cessation. |
10 mg orally three times daily, with or without food.
| Dosage form | TABLET |
| Renal impairment | GFR 30-49 mL/min: 10 mg twice daily; GFR <30 mL/min: 10 mg once daily; Hemodialysis: 10 mg once daily after dialysis. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: 10 mg twice daily; Child-Pugh C: not recommended. |
| Pediatric use | 1-2 mg/kg/day divided every 8 hours, maximum 30 mg/day. |
| Geriatric use | No specific adjustment; caution in age >75 years due to increased fall risk; monitor renal function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for VANRAFIA (VANRAFIA).
| Breastfeeding | Unknown if excreted in human milk; M/P ratio not established. Due to potential for serious adverse reactions in nursing infants, breastfeeding is not recommended during treatment and for at least 7 days after last dose. |
| Teratogenic Risk | Vanrafia (roflumilast) is contraindicated in pregnancy. First trimester: Associated with increased risk of congenital malformations, particularly cardiac and skeletal defects, based on animal studies. Second and third trimesters: Risk of fetal toxicity and low birth weight. Use only if maternal benefit outweighs fetal risk, with informed consent. |
■ FDA Black Box Warning
None
| Serious Effects |
["Severe renal impairment (eGFR <30 mL/min/1.73 m²)","End-stage renal disease or dialysis","Hypersensitivity to Vanrafia or any component","History of serious hypersensitivity reactions (e.g., anaphylaxis)"]
| Precautions | ["Risk of diabetic ketoacidosis (DKA), including atypical presentations with euglycemia","Acute kidney injury, especially in volume-depleted patients","Increased risk of lower limb amputations (observed in clinical trials)","Necrotizing fasciitis of the perineum (Fournier gangrene)","Genital mycotic infections, particularly in uncircumcised males","Hypotension and volume depletion","Elevated LDL cholesterol"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal liver function tests (ALT, AST) monthly; perform renal function tests; assess for psychiatric symptoms (anxiety, depression, suicidality). Fetal monitoring with ultrasound for growth restriction and anomalies if exposure occurs; consider fetal echocardiography. |
| Fertility Effects | In animal studies, roflumilast did not significantly impair fertility; however, due to anti-inflammatory effects, theoretical risk of altered gonadal function. Human data limited; advise patients of potential for reversible effects on spermatogenesis or ovulation. |